| Identification | Back Directory | [Name]
(S)-1-((2S,3S,11bS)-2-amino-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-3-yl)-4-(fluoromethyl)pyrrolidin-2-one | [CAS]
813452-18-5 | [Synonyms]
R1579
R-1579
RG1579
RG-1579
RO-4876904
Camegliptin
CARMEGLIPTIN
RO-4876904-001
2-Pyrrolidinone, 1-[(2S,3S,11bS)-2-amino-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-2H-benzo[a]quinolizin-3-yl]-4-(fluoromethyl)-, (4S)-
(S)-1-((2S,3S,11bS)-2-amino-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-3-yl)-4-(fluoromethyl)pyrrolidin-2-one | [Molecular Formula]
C20H28FN3O3 | [MDL Number]
MFCD16038044 | [MOL File]
813452-18-5.mol | [Molecular Weight]
377.45 |
| Hazard Information | Back Directory | [Uses]
Carmegliptin (RO-4876904) is an orally active, potent and long-acting dipeptidyl peptidase IV inhibitor. Carmegliptin is also a substrate of P-glycoprotein that synergizes with Verapamil (HY-14275). Carmegliptin improves insulin sensitivity and reduces hepatic glucose production in hyperglycemic mice. Carmegliptin is promising for research of type 2 diabetes, hypertension and cardiovascular disease[1][2]. | [IC 50]
DPP-4 | [References]
[1] Mattei P, et al. Discovery of carmegliptin: a potent and long-acting dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1109-13. DOI:10.1016/j.bmcl.2009.12.024
[2] Kuhlmann O, et al. Interaction potential of Carmegliptin with P-glycoprotein (Pgp) transporter in healthy volunteers. J Drug Assess. 2014 Mar 3;3(1):28-37. DOI:10.3109/21556660.2014.900065 |
|
|